Garcia VC, Mansfield C, Leach C, Pierce A, Smith JC, Afonso M. Patient and caregiver preferences for hemophilia treatments: a discrete-choice experiment. Haemophilia. 2024 Mar;30(2):375-87. doi: 10.1111/hae.14928
Dheyriat L, Ward D, Beaugerie L, Jess T, Kirchgesner J. Risk of recurrent acute arterial events associated with thiopurines and anti-tumor necrosis factor in inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2023 Jan;21(1):164-172.e. doi: 10.1016/j.cgh.2022.06.011
Salas M, Mordin M, Castro C, Islam Z, Tu N, Hackshaw MD. Health-related quality of life in women with breast cancer: a review of measures. BMC Cancer. 2022 Jan 15;22(1):66. doi: 10.1186/s12885-021-09157-w
Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib in hepatocellular carcinoma patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2021 Nov 20. doi: 10.1016/j.cgh.2021.11.020
Hackshaw MD, Danysh HE, Henderson M, Wang E, Tu N, Islam Z, Ladner A, Ritchey ME, Salas M. Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review. BMC Cancer. 2021 Aug 28;21(1):967. doi: 10.1186/s12885-021-08708-5
Vickers AD, Winfree KB, Cuyun Carter G, Kiiskinen U, Jen MH, Stull D, Kaye JA, Carbone DP. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis. BMC Cancer. 2019 Apr 15;19(1):353. doi: 10.1186/s12885-019-5569-5.
Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015 May;21(3):310-9. doi: 10.1111/hae.12621
McGowan CE, Edwards TP, Luong MU, Hayashi PH. Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers. Clin Gastroenterol Hepatol. 2015 Apr;13(4):799-804. doi: 10.1016/j.cgh.2014.07.056
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590
Layton JB, Klemmer PJ, Christiansen CF, Bomback AS, Baron JA, Sandler RS, Kshirsagar AV. Sodium phosphate does not increase risk for acute kidney injury after routine colonoscopy, compared with polyethylene glycol. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1514-21. doi: 10.1016/j.cgh.2014.01.034
DiBenedetti DB, Coles TM, Sharma T, Pericleous L, Kulkarni R. Assessing patients' and caregivers' perspectives on stability of factor VIII products for haemophilia A: a web-based study in the United States and Canada. Haemophilia. 2014 Jul;20(4):e296-303. doi: 10.1111/hae.12459
Brown TM, Pashos CL, Joshi AV, Lee WC. The perspective of patients with haemophilia with inhibitors and their care givers: preferences for treatment characteristics. Haemophilia. 2011 May 1;17(3):476-82.
Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia. 2009 Jul 1;15(4):911-7.
Jorgensen E, Stinson A, Shan L, Yang J, Gietl D, Albino AP. Cigarette smoke induces endoplasmic reticulum stress and the unfolded protein response in normal and malignant human lung cells. BMC Cancer. 2008 Aug 11;8:229. doi: 10.1186/1471-2407-8-229
Lee WC, Joshi AV, Woolford S, Sumner M, Brown TM, Hadker N, Pashos CL. Physicians' preferences towards coagulation factor concentrates in the treatment of haemophilia with inhibitors: a discrete choice experiment. Haemophilia. 2008 May 1;3(14):454-65.
Fortuny J, Johnson CC, Bohlke K, Chow WH, Hart G, Kucera G, Mujumdar U, Ownby D, Wells K, Yood MU, Engel LS. Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1154-1159. doi: 10.1016/j.cgh.2007.05.022
Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol. 2007 May 1;5(5):534-40.